LMO2 confers value as a potential immunotherapy marker in pan-cancer analysis and inhibits progression of Clear Cell Renal Cell Carcinoma

Abstract Full pan-cancer analysis of LMO2 with immunotherapeutic target assessment. ZC3h13 mediated m6A modification controls LMO2 expression in ccRCC. LMO2 downregulation enhances NF-κB pathway via GATA2-BEX1 axis in ccRCC. Article type: Brief Report Keywords: Lim-domain only 2, Bioinformatics, Prognosis, Cancer immunity, m, BEX-1, NF-κB Authors: Huiping Wang, Cong Wang, Jia Wei, Xuan’er Zhao, Xuemei Yang, Renren Li, Mengmeng Li, Zhansheng Zhu Affiliations: Jiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Key Laboratory of Genetic Foundation and